Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Colorectal Neoplasms 9Rectal Neoplasms 4Uterine Cervical Neoplasms 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Diabetes Mellitus, Insulin-Dependent, 12 2Colonic Neoplasms 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Sarcoma 1Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Oropharyngeal Neoplasms 1Neoplasms 1Microsatellite Stable Rectal Carcinoma 1Melanoma 1Lymphoma 1Hemangiosarcoma 1Gliosarcoma 1Glioblastoma 1Esophageal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Advanced Renal Cell Carcinoma 1Adenocarcinoma Of Esophagus 1

Interventions

Paclitaxel 6Doxorubicin 6Gemcitabine 4Bevacizumab 4pembrolizumab 3pazopanib 3durvalumab 3Sorafenib 3Docetaxel 3trebananib 2spartalizumab 2cemiplimab 2brostallicin 2Propranolol 2Nivolumab 2Magnetic Resonance Spectroscopy 2Ipilimumab 2Imatinib Mesylate 2Ifosfamide 2Carboplatin 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2zanidatamab 1veliparib 1tucatinib 1trilaciclib 1tremelimumab 1trastuzumab duocarmazine 1temsirolimus 1talimogene laherparepvec 1talazoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hemangiosarcoma × balstilimab × Clear all
NCT04607200 2022-01-11

AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma

Agenus Inc.

Phase 2 Withdrawn
Sarcoma

Hemangiosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡